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Abstract  
Aims: To address the effect of a diet enriched in extra virgin olive oil (EVOO) on 
maternal metabolic parameters and placental proinflammatory markers in Gestationa l 
diabetes mellitus (GDM) patients. Methods: Pregnant women at 24-28 weeks of 
gestation were enrolled: 33 GDM patients which were randomly assigned or not to the 
EVOO-enriched group and 17 healthy controls. Metabolic parameters were determined. 
Peroxisome proliferator activated receptor (PPAR) γ and PPARα protein expression, 
expression of microRNA (miR)-130a and miR-518d (which respectively target these 
PPAR isoforms) and levels of proinflammatory markers were evaluated in term placentas. 
Matrix metalloproteinases (MMPs) activity was evaluated in term placentas and umbilica l 
cord blood. Results: GDM patients that received the EVOO-enriched diet showed 
reduced pregnancy weight gain (GDM-EVOO:10.3±0.9, GDM:14.2±1.4, P=0.03) and 
reduced triglyceridemia (GDM-EVOO:231±14, GDM:292±21, P=0.02) compared to the 
non-EVOO-enriched GDM group. In GDM placentas, the EVOO-enriched diet did not 
regulate PPARγ protein expression or miR-130a expression, but prevented the reduced 
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PPARα protein expression (P=0.02 vs GDM) and the increased miR-518d expression 
(P=0.009 vs GDM). Increased proinflammatory markers (interleukin-1β, tumor necrosis 
factor-α and nitric oxide overproduction) in GDM placentas were prevented by the 
EVOO-enriched diet (respectively P=0.001, P=0.001 and P=0.01 vs GDM). MMPs 
overactivity was prevented in placenta and umbilical cord blood in the EVOO-enriched 
GDM group (MMP-9: respectively P=0.01 and P=0.001 vs GDM). Conclusions: A diet 
enriched in EVOO in GDM patients reduced maternal triglyceridemia and weight gain 
and has anti-inflammatory properties in placenta and umbilical cord blood, possibly 




Gestational diabetes mellitus (GDM) is a prevalent disease that increases the risks 
of maternal, placental, and perinatal adverse outcomes and induces long-term adverse 
effects on the offspring´s later life1,2. Adverse outcomes in GDM have been related to an 
intrauterine proinflammatory environment3. Indeed, proinflammation is a common 
alteration in gestational diseases and can influence the placental development and 
function, the fetal development and the offspring´s later life4,5.  
Our previous studies performed in experimental models of diabetes and pregnancy 
allowed us to identify changes in pathways regulated by peroxisome proliferator activated 
receptors (PPARs) in embryos, fetuses and placentas, related to a proinflammatory 
environment6. PPARs are ligand activated transcription factors capable of regulat ing 
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metabolic and anti-inflammatory pathways, as well as intrauterine development7,8 . 
PPARs are nutrigenomic agents, being monounsaturated fatty acids (MUFAs, the main 
components of olive oil), PPARs endogenous ligands9,10. In experimental models of 
diabetes and pregnancy, our previous studies have shown that diets enriched in extra 
virgin olive oil (EVOO) lead to anti-inflammatory effects, as shown by the ability of these 
diets to prevent increased levels of proinflammatory cytokines, nitric oxide 
overproduction, and matrix metalloproteinases (MMPs) overexpression in placentas, 
embryos and different fetal organs11-16. Studies have also shown that although maternal 
EVOO-dietary treatments do not prevent programming of metabolic diseases in the 
offspring of diabetic animals, this treatment reduces the levels of proinflammatory 
markers in the offspring´s heart and prevents hypertriglyceridemia in the adult offspring 
of diabetic rats11,16.   
In women with pregestational and gestational diabetes, placental levels and 
expression of PPARγ and PPARα are reduced17,18. Besides, expression of microRNA-
518d, a microRNA that targets PPARα, is increased in the placentas of GDM patients19 . 
Whether microRNAs that regulate PPARs are related to PPARγ changes and whether 
alterations in placental microRNAs that target PPARs can be prevented by diets enriched 
in PPAR ligands are unknown.  
EVOO is the main vegetable oil that composes the Mediterranean diet, which is 
increasingly being considered as a medical treatment20,21. The Mediterranean diet has 
been found associated with a lower incidence of GDM22. Out of pregnancy, an EVOO-
enriched diet has beneficial effects on metabolic and cardiovascular diseases, as 
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demonstrated in the PREDIMED study and other clinical studies23-25. In pregnant women, 
studies addressing a diet enriched in EVOO and pistachios reduced the incidence of 
GDM26. No previous studies addressing a putative beneficial effect of an EVOO-enriched 
diet in GDM pregnancies have been conducted so far. In this work, we conducted a 
randomized clinical trial and tested the hypothesis that a maternal diet enriched in EVOO 
ameliorates triglyceridemia in the mothers, regulates placental PPAR protein levels, 
modulates the expression of microRNAs that regulate PPARs expression, and reduces 





2.1 Study design  
Pregnant women with a singleton fetus at the time of GDM diagnosis (between 24 to 28 
weeks) were randomly assigned in a 1:1 manner to receive a diet with additional three 
tablespoons of crude EVOO daily (36 g/day). GDM was diagnosed according to Latin 
American Diabetes Association (ALAD)/ Argentine Society of Diabetes (SAD) 
diagnostic criteria, based on glycemia values either at fasting (>99 mg/dl in two 
measurements) or after the universal p75 g oral glucose tolerance test (>140 mg/dl at 2 
h)27. Control women were recruited at the same gestational age. Exclusion criteria 
included BMI over 30 kg/m2 before pregnancy, multiple pregnancies and concurrent 
pathologies including: thrombophilia, preeclampsia, pregestational diabetes, vascular or 
This article is protected by copyright. All rights reserved.
 
 
renal complications associated with chronic hypertension, anemia with total hemoglob in 
below 8 g/dL and positive serology for HIV, VDRL, Hepatitis B or Chagas disease. 
Potential participants received written and oral information about the trial and had at least 
24 h to decide their participation. This clinical trial was approved on 14th January 2016 
by the Ethics and Research Committee of the Pirovano Hospital (Review Board Project: 
DI-2016-29-HGAIP) and registered at the Ministry of Health of the City of Buenos Aires 
on October 2016, IF-2016-22533767. Participants were recruited at Hospital de Agudos 
Dr. Ignacio Pirovano, Buenos Aires, Argentina, from December 2016 to December 2018. 
The study was undertaken in accordance with the Declaration of Helsinki and followed 
the 2010 Consort guidelines. All women that agreed to participate provided their written 
informed consent. 
All eligible women received standardized personal advice on healthy eating and 
appropriate medical care. The study was not blinded, as those women in the EVOO-
enriched group received commercial bottles of EVOO at the nutrition visits to ensure 
adherence. In the three experimental groups (Control, GDM, GDM-EVOO), the women 
received dietary indications to follow a nutritional plan with the following composition: 
2100-2400 Kcal/day; carbohydrates 48-50%, proteins 18-20% and lipids 30-32%. In the 
intervention group, women were indicated to include three tablespoons of EVOO daily 
(36 g/day). The EVOO was indicated to be consumed uncooked and within the main 
meals. The group that did not receive the EVOO-enriched diet was indicated to include 
none to one tablespoon of EVOO daily (0 to 12 g per day). Follow-up appointments to 
the obstetrics and nutrition professionals in charge of the study were frequent (every 1 to 
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4 weeks according to the gestational age and requirements). To assess adherence to the 
EVOO dietary intervention, questionnaires were performed and diet composition was 
evaluated at each nutritional visit. Adherence was considered good if reports indicated a 
daily EVOO consumption over 26 g/day 5 to 7 times a week, regular if daily EVOO 
consumption was over 26 g/day 3 or 4 times a week and bad if daily EVOO consumption 
was lower than 26 g/day or lower than 3 times a week. Clinical data of the participants 
were recorded at each visit. At GDM diagnosis, women received the dietary treatment 
and the indications for glucose monitoring. In subsequent visits, insulin was added if 
target blood-glucose values were not achieved27.  
 
2.2 Metabolic parameters and pregnancy outcomes 
Eight-hour fasting blood was collected at enrolment (gestational weeks 24 to 28) and at 
gestational week 37. Plasma glucose, fructosamine and glycated hemoglobin were 
evaluated using an Abbott autoanalyzer (Architect C8000). Triglycerides were evaluated 
by colorimetric methods (Wiener lab, Rosario, Argentina). Gestational weight gain 
(defined as the difference in maternal weight between the reported weight at term and 
prior to pregnancy) was determined. Maternal and fetal complications were reported. 
Neonatal and placental weight were obtained at birth.   
 
2.3 Placenta and umbilical cord blood sampling 
Umbilical cord blood was collected before placental delivery and citrate plasma 
immediately obtained and conserved at -80°C. Placental tissues were collected from 
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centrally located cotyledons, avoiding decidua and membrane layers. Placental tissues 
were stored in 10% formalin for immunohistochemical studies, immersed in RNA-later® 
solution and stored at -80°C for PCR studies, or immediately stored at -80°C for Western 
Blot, zymography and nitric oxide production evaluation.  
 
2.4 Western blot analysis 
Placental explants were homogenized, proteins were separated by SDS-PAGE and 
transferred to nitrocellulose membranes (35V constant, overnight at 4°C), as previously 
described28. The membranes were stained with Ponceau Red staining solution for total 
proteins (Sigma-Aldrich, St Louis, MO, USA) to confirm proper transfer. After blocking 
for 1 h the membranes were incubated overnight at 4°C with PPARγ antibody (1:100, 
Cayman Chemical Co., MI, USA), PPARα antibody (1:100, Cayman Chemical Co.) or 
actin antibody (1:500, Sigma-Aldrich), which was used as a loading control. After 
washing, the membranes were incubated with the appropriate peroxidase conjugated 
secondary antibody, visualized using ECL detection solution (Thermo Scientific) and 
captured in an ImageQuant LAS 4000 (GE Healthcare Life Sciences, NJ, USA). The 
relative intensity of protein signals was quantified by densitometric analysis using the 
ImageJ Software (NIH, MD, USA). Results are expressed as protein of interest /actin 
protein ratio. 
 
2.5 Total RNA and microRNA isolation, and qRT-PCR analysis 
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Total RNA and microRNA were isolated from placental explants (100 mg) using 
RNAzol® (MCR Inc., OH, USA) and their concentrations determined using the 
NanoDrop spectrophotometer.  
For microRNA evaluation, cDNA was obtained using the TaqMan MicroRNA reverse 
transcription kit (Applied Biosystems, CA, USA). The relative expression of miR-130a 
and of miR-518d was determined using the TaqMan detection system (Applied 
Biosystems), the appropriate primers (assay ID 000454 and 002389 respectively), and the 
U6 spliceosomal RNA (assay ID 001973) as endogenous control (Applied Biosystems).  
From total RNA, cDNA was synthesized incubating 1 μg of extracted RNA in a buffer 
containing 200 U MML-V enzyme (Promega, WI), 7.5 mM random primer hexamers and 
0.5 mM of each dNTPs, as previously28. The reaction mixture was incubated for 60 min 
at 37°C followed by 15 min at 70°C. Then, 2.5 μl of cDNA was used to perform the 
amplification in 10 μl reaction buffer containing dNTPs mix 20 mM, GoTaq Polymerase 
(Promega), Eva Green 20x, and gene specific primer (Cu/Zn SOD, forward: 5′-
ACAAAGATGGTGTGGCCGAT-3′, reverse: 5′-AACGACTTCCAGCGTTTCCT-3′). 
The qPCR conditions started with a denaturation step at 95°C for 5 min and followed by 
up to 40 cycles of denaturation (95°C), annealing (62°C) and primer extension (72°C). 
mRNA levels were normalized to the 60s ribosomal protein L30 levels (L30 primer: 
forward: 5′- TGATCAGACAAGGCAAAGCG-3′, reverse: 5′- 
GCCACTGTAGTGATGGACACC-3′).   
From total RNA and microRNA, the course of PCR amplification was followed in each 
cycle by the fluorescence measurement on Corbett Rotor-Gene 6000 (QIAGEN, MD). 
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Gene expression was quantified using the 2-ΔΔCt method. Relative mRNA and microRNA 
levels are reported as fold value of the control. 
 
2.6 Immunohistochemistry 
Placentas were paraffinized and serially cut in 5-μm-thick sections for further evaluation 
of interleukin 1β (IL-1β) and tumor necrosis factor-alpha (TNF-α) immunostaining. 
Sections were deparaffinized, rehydrated through a graded series of ethanol and the 
endogenous peroxidase activity was blocked. The sections were processed overnight 
using anti-TNF-α primary antibody (mouse  monoclonal antibody, 1:100 dilution, Santa 
Cruz Biotechnology, CA, USA) and anti-IL-1β primary antibody (mouse monoclona l 
antibody, 1:100 dilution, Santa Cruz Biotechnology)  in a humidified chamber at room 
temperature and then incubated with the biotinylated anti-mouse secondary antibody 
(anti-mouse IgG, dilution 1:200, Vector Laboratories, CA) for 1 h. Sections were 
incubated with the Avidin-Biotin-Complex (Vectastain, Vector Laboratories, USA) for 1 
h and then the stain was developed with 3,3’-diaminobenzidine, as previously described15. 
Control sections were generated by omitting the primary antibody. Two skilled blinded 
observers evaluated three sections per placenta. Immunoreactivity intensity was 
quantified with the ImageProPlus software. Data are shown as relative to a value of 1 
assigned to the mean values in the control group.  
 
2.7 Nitric oxide production 
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Nitric oxide production was determined by measuring the concentration of its stable 
metabolites nitrates/nitrites, as reported previously28. Briefly, placental explants were 
homogenized in 1 ml Tris-HCl buffer pH 7.6, and an aliquot was separated for protein 
analysis. After reducing nitrates to nitrites by using nitrate reductase enzyme, nitrites were 
measured by the Griess reaction using a commercial assay kit (Cayman Chemical Co.). 
 
2.8 Gelatinase activity of matrix metalloproteinases  
Zymography was performed to evaluate the gelatinase activity of matrix 
metalloproteinases (MMP) 2 and 9, as previously described15. Briefly, placental explants 
were homogenized in 50 mM Tris, 5 mM CaCl2, 1 μM ZnCl2 and 1% Triton X-100. Then, 
30 µg of protein of the homogenates was mixed with loading buffer (2% SDS, 10% 
glycerol, 0.1% bromophenol blue, 50 mM Tris-HCl, pH 6.8) and subjected to a 7.5% 
SDS-PAGE containing 1 mg/ml gelatin (type A from porcine skin). Gels were rinsed, 
stained with Coomassie blue and destained with 10% acetic acid and 30% methanol in 
water. The areas of proteolytic activity appeared as negatively stained bands in a dark 
background. MMPs were identified by their molecular weights and a positive interna l 
control (conditioned medium of human fibrosarcoma HT-1080 cells). The enzymatic 
activity was quantified using ImageJ software and expressed as arbitrary densitometr ic 
units. Data are shown as relative to a value of 1 assigned to the mean value for MMP 
activity in the control group.   
 
2.9 Study endpoints 
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The primary endpoint was a change in PPARγ and PPARα levels and placental markers 
of a prooxidant/proinflammatory state (TNFα and IL-1β levels, nitric oxide production, 
SOD expression, and MMPs gelatinase activity). Second endpoints were changes in 
maternal metabolic control, triglyceridemia, maternal weight gain, neonatal and placental 
weight as well as microRNAs that target PPARγ and PPARα (miR-130a and miR-518d 
respectively).  
 
2.10 Statistical analysis 
Data are presented as the mean ± SEM. Groups were compared by one-way ANOVA 
followed by Bonferroni´s post-hoc test to compare all groups to each other, Student´s t-
test or chi-square test as appropriate (Graphpad Prism 8 software). Normality of the 
variable distribution was corroborated with the Shapiro-Wilk test. Homogeneity of 
variance was evaluated with the Levene´s test, and in the cases where homogeneity of 
variance was not verified, the variance function Varldent was applied to the model 





3.1 Metabolic parameters and pregnancy outcomes  
As shown in the study Flow chart (Supplementary Figure 1), we were able to obtain the 
complete samples at term of 45 women (15 of the Control group, 15 of the GDM group 
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and 15 of the GDM-EVOO-enriched group (GDM-EVOO). Adherence to the EVOO 
dietary intervention was good in 80% of the GDM patients (Table 1). Age and pre-
pregnancy weight were similar between the three groups (Table 1). Total weight gain was 
increased in the GDM group (P=0.02 GDM vs. Control), an alteration prevented by the 
maternal diet enriched in EVOO (P=0.03 GDM-EVOO vs. GDM) (Table 1). A very good 
metabolic control was achieved in both the GDM and the GDM-EVOO group, as shown 
by the fasting blood glucose, fructosamine and HbA1c levels at term (Table 1). GDM 
patients were treated with diet or diet and insulin, with no significant changes between 
the two groups (P=0.14, Table 1). At enrolment, triglyceridemia values in the groups 
evaluated showed no changes (Table 1). Differently, at term, triglyceridemia was 
increased in the GDM group compared to Controls (P=0.04), an alteration prevented in 
the GDM group that received the EVOO-enriched diet (P=0.02 GDM-EVOO vs. GDM) 
(Table 1). Regarding the pregnancy outcomes, gestational age at delivery, Cesarean 
delivery rate, maternal complications, neonatal complications, neonatal weight and 
placental weight were similar in the three groups evaluated (Table 2).  
 
3.2 PPARs and microRNAs that regulate PPARs expression 
We next addressed PPAR pathways, and found reduced protein expression of PPARγ in 
the placentas from GDM patients that received or not the diet enriched in EVOO 
compared to controls (P=0.007 GDM vs. Control, P=0.03 GDM-EVOO vs. Control, 
Figure 1). Differently, the reduced protein expression of PPARα in the placentas from 
GDM patients was prevented by the diet enriched in EVOO (P=0.02 GDM vs. Control, 
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P=0.02 GDM- EVOO vs. GDM, Figure 1). To determine whether microRNAs that target 
PPARs are involved in the changes observed, we evaluated the expression of miR-130a, 
which targets PPARγ in different tissues29, and of miR-518d, which targets PPARα in the 
placenta19. The expression of miR-130a showed no changes in the groups evaluated 
(Figure 1), but miR-518d expression, which was increased in the placenta of GDM 
patients (P=0.003 vs. Control), was reduced in the placentas of the GDM patients that 
received the EVOO-enriched diet (P=0.009 vs. GDM, Figure 1).  
 
3.3 Regulation of the proinflammatory environment 
As PPARs are largely involved in the regulation of the proinflammatory environment and 
the EVOO diet is enriched in MUFAs, which are PPAR ligands, we next evaluated 
proinflammatory markers in term placentas from the GDM patients that received or not 
the EVOO-enriched diet. We found that TNF-α levels were increased in the placentas 
from GDM patients compared to controls (P=0.0002), an alteration prevented by the 
maternal diet enriched in EVOO (P=0.0002 vs. GDM) (Figure 2). Similarly, IL-1β levels 
were increased in the GDM group compared to controls (P=0.0001), an alteration 
prevented by the maternal diet enriched in EVOO (P=0.0001 vs. GDM) (Figure 2). The 
production of nitric oxide was increased in the GDM group compared to controls 
(P=0.03), an alteration prevented by the maternal diet enriched in EVOO (P=0.01 vs. 
GDM) (Figure 2). Moreover, the gene expression of the antioxidant enzyme Cu-Zn 
superoxide dismutase was reduced in the placentas from GDM patients compared to 
controls (P=0.004), an alteration prevented by the maternal diet enriched in EVOO 
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(P=0.004 vs. GDM) (Figure 2). Finally, the activity of MMPs was measured both in the 
placenta and the umbilical cord blood. MMP-2 activity showed no changes, whereas 
MMP-9 activity was increased in the placentas from GDM patients compared to controls 
(P=0.003), an alteration prevented by the maternal diet enriched in EVOO (P=0.01 vs. 
GDM) (Figure 3). Moreover, MMP-2 and MMP-9 activities were increased in the 
umbilical cord blood from GDM patients compared to controls (P=0.03 and P=0.009 
respectively), alterations prevented by the maternal diet enriched in EVOO (P=0.03 and 




The study presented here is the first to address the effects of an EVOO-enriched diet in 
GDM pregnancies. In GDM mothers, the EVOO-enriched diet reduced triglyceridemia 
and weight gain. In the placenta of GDM patients, the maternal EVOO-enriched diet did 
not regulate miR-130a expression or PPARγ levels, but did regulate miR-518d expression 
and PPARα levels. Anti-inflammatory effects were observed in the placenta and the 
umbilical cord blood in the GDM patients that received the EVOO-enriched diet. If 
replicated in a larger number of patients, these results would have important clinica l 
implications as a feasible dietary treatment that provides benefits to GDM mothers and 
their placentas, with possible beneficial effects on the offspring´s later life.  
Maternal nutrition is crucial in GDM metabolic control. Modified diet interventions 
favorable influence outcomes related to maternal glycemia and birth weight30 and the 
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follow up of nutritional advices, such as consumption of low-glycemic index 
carbohydrates, has largely improved the metabolic control in this prevalent gestationa l 
disease31,32. In the last years, the nutrigenomic concepts brought to a new dimension the 
interaction of nutrients and the genome, with implications in multiple diseases, includ ing 
GDM33. PPARs are ligand activated transcription factors that respond to nutrients to bring 
transcriptional regulation of metabolic, developmental and proinflammatory pathways7. 
Endogenous PPAR ligands have lipid nature and can be incorporated through the diet9. 
Dietary unsaturated fatty acids are endogenous PPAR ligands that can efficiently be 
transferred through the placenta and the fetus to act as PPAR activators6,34. Considering 
this, the low levels of PPARα and PPARγ previously observed in the placentas from 
GDM patients17 provide a rationale to provide PPAR agonists from the maternal diet to 
the placenta in GDM pregnancies.  
Our previous studies performed in experimental models of diabetes and pregnancy 
have shown that a maternal EVOO dietary treatment regulates PPAR pathways and 
reduces proinflammatory markers in rat embryos, fetuses, placentas and in the offspring´s 
heart6,11-13,15. The dose of olive oil that shows these beneficial effects in animal models of 
diabetes and pregnancy provides half of the lipid-derived calories (5% in an 11% lipid 
content diet). Based on this, in this translational clinical study, we provided a diet that 
brings about half of the lipid-derived calories by the olive oil (14% in a 30% lipid content 
diet). This amount of EVOO added to the diet was similar to that reported to be benefic ia l 
in different clinical studies, including those evaluating the ability of an EVOO-enriched 
diet to prevent GDM induction in a general population21,26. 
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The PREDIMED and other clinical studies have addressed the ability of EVOO- enriched 
diets to ameliorate cardiovascular diseases and improve lipid metabolic profiles 21,23,25. 
Here, the fact that triglycerides and weight gain are reduced to control values in the GDM 
patients that received the EVOO-enriched diet is clinically relevant and deserves to be 
studied in larger populations. The mechanisms involved are likely to be related to effects 
on maternal target organs, including the liver, through mechanisms which are possibly 
related to the activation of PPARα35.  
Other pregnancy outcomes, including gestational age, Cesarean delivery, maternal and 
neonatal complications, and neonatal and placental weight did not change between the 
groups evaluated, and a larger number of patients would be needed to address putative 
changes in these and other maternal/perinatal outcomes. Indeed, a limitation of this work 
was the limited number of patients included in this study. Another limitation is that we 
did not quantify overall caloric intake and macronutrient consumption, and thus we 
cannot rule out that differences in caloric intake could explain some of the benefits 
observed. A third limitation of this work is the lack of use of operator-independent 
biomarkers of fatty acid consumption such as circulating fatty acids36.  
In this study, we focused in the placenta and the putative changes in PPARs 
expression. Similar to that previously found in a rat model of GDM11, we here found that 
the maternal EVOO-enriched diet did not prevent the reduced PPARγ levels, but induced 
anti-inflammatory effects in the placenta. Indeed, PPAR ligands are provided by the 
EVOO-enriched diet, and thus, even without changing PPARγ levels, the activity of this 
nuclear receptor may be increased, in turn leading to the observed anti-inflammatory 
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effects37. Besides, the expression of miR-130, a microRNA that targets PPARγ and is 
related to PPARγ changes in the livers of GDM rats29, was similar in the three groups 
evaluated, suggesting that other epigenetic regulators are those related to the observed 
PPARγ changes induced by GDM. Zhao et al. showed that the reduced PPARα levels in 
GDM placentas are related to increased levels of miR-518d19. In this work, together with 
confirming this result, we found that the EVOO-enriched diet was able to prevent both 
increased miR-518d expression and reduced PPARα levels. This points to the miR-
518d/PPARα pathway as a relevant component in the placental anti-inflammatory effects 
observed.  
In non-pregnant subjects, EVOO-enriched diets have been found to exert potent anti-
inflammatory effects in different tissues21,24. In this work, the anti-inflammatory effects 
observed in the placentas from the GDM patients that received the EVOO-enriched diet 
included reductions in cytokine levels, regulation of antioxidant enzymes gene expression 
and reduction of nitric oxide overproduction. These proinflammatory markers have been 
previously found altered in GDM placentas and are difficult to modulate even with a good 
metabolic control3,5. Also, the ability of the EVOO-enriched diet to prevent MMPs 
activity in the placenta and the umbilical cord blood observed in GDM patients is 
supported by previous studies addressing the effect of diets added with EVOO as negative 
regulators of MMPs in placentas from diabetic rats and in different human diseases15,38, 
and provides evidence of the capacity of the benefits of the EVOO-enriched diet to reach 
the fetal compartment.  
 





This randomized clinical study allowed identifying, for the first time, the ability of an 
EVOO-enriched diet in GDM pregnancies to reduce maternal triglyceridemia and weight 
gain, which are clinically relevant parameters, thus suggesting a putative benefit that 
should be addressed in larger populations. Also, this clinical study provides evidence of 
the capacity of an EVOO-enriched diet to induce placental anti-inflammatory effects, at 
least partly mediated by the activation/regulation of PPAR pathways. Anti-inflammatory 
effects were also evidenced in the umbilical cord blood, suggesting benefits in the 
perinatal period and the offspring´s later life. Further studies addressing long term effects 
of this dietary treatment will be needed to establish its clinical significance in the 
offspring´s later life.  
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Supplementary Figure 1. Flow chart and trial overview  
 
FIGURE 1. Protein expression of PPARγ and PPARα and expression of microRNAs that 
target these PPAR isotypes in term placentas of GDM patients that received or not a 
maternal diet enriched in three tablespoons of EVOO per day from weeks 24-28 of 
pregnancy until term and in controls. a. PPARγ. b. PPARα. c. miR-130a (targeting 
PPARγ). d. miR-518d (targeting PPARα). Values represent mean ± SEM. Statistica l 
analysis: one-way ANOVA in conjunction with Bonferroni´s test.  ‡P<0.05 and ‡‡P <0.01 
vs. Control, §P<0.05, §§P<0.01 vs. GDM. 
 
FIGURE 2. Evaluation of proinflammatory and prooxidant markers in term placentas of 
GDM patients that received or not a maternal diet enriched in three tablespoons of EVOO 
per day from weeks 24-28 of pregnancy until term and in controls. a. TNF-α. 
Representative images and densitometric analysis. b. IL-1β. Representative images and 
densitometric analysis. c. Nitric oxide production (evaluated through the determina t ion 
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of its stable metabolites nitrates/nitrites). d. Gene expression of Cu-Zn SOD. Values 
represent mean ± SEM. Statistical analysis: one-way ANOVA in conjunction with 
Bonferroni´s test. ‡P<0.05 and ‡‡P<0.01, ‡‡‡P<0.001 vs. Control. §P<0.05 and §§P<0.01, 
§§§P<0.001 vs. GDM. 
 
FIGURE 3. Gelatinase activity of MMP-2 and MMP-9 in term placentas and umbilica l 
cord blood in GDM patients that received or not a maternal diet enriched in three 
tablespoons of EVOO per day from weeks 24-28 of pregnancy until term and in controls. 
a. MMP-2 in term placentas. b. MMP-9 in term placentas. c. MMP-2 in umbilical cord 
blood. d. MMP-9 in umbilical cord blood. Values represent mean ± SEM. Statistica l 
analysis: one-way ANOVA in conjunction with Bonferroni´s test. ‡P<0.05 and ‡‡P<0.01 
vs. Control. §P<0.05 and §§P<0.01 vs. GDM. 
  





















Age (years) 27.4±1.9 29.6±1.6 31.1±1.6 
>0.99 GDM vs. Control 
>0.99 GDM-EVOO vs. GDM 
0.39 GDM-EVOO vs. Control 
Pre-pregnancy weight (kg) 57.5±1.9 62.3±2.0 61.3±2.0 
0.27 GDM vs. Control 
>0.99 GDM-EVOO vs. GDM 
0.53 GDM-EVOO vs. Control 
Total weight gain (kg) 9.9±0.7 14.2±1.4 10.3±0.9 
0.02 GDM vs. Control 
0.03 GDM-EVOO vs. GDM 
>0.99 GDM-EVOO vs. Control 
Fasting blood glucose at 
enrolment (mg/dL) 
81.4±1.9 88.0±2.7 86.0±1.8 
0.11 GDM vs. Control 
>0.99 GDM-EVOO vs. GDM 
0.43 GDM-EVOO vs. Control 
Fasting blood glucose 
at term (mg/dL) 
81.3±1.6 89.0±3.6 87.6±2.7 
0.16 GDM vs. Control 
>0.99 GDM-EVOO vs. GDM 
0.34 GDM-EVOO vs. Control 
Blood fructosamine at 
enrolment (mg/dL) 
- 183.0±6.1 181.1±4.2 0.80 GDM-EVOO vs. GDM 
Blood fructosamine 
at term (mg/dL) 
- 185.8±5.8 189.6±2.6 0.55 GDM-EVOO vs. GDM 
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HbA1c at enrolment (% ) - 5.0±0.08 4.9±0.10 0.44 GDM-EVOO vs. GDM 
HbA1c at term (% ) - 5.4±0.10 5.5±0.06 0.39 GDM-EVOO vs. GDM 
Blood triglycerides 
at enrolment (mg/dL) 
185±8 209±10 219±15 
0.43 GDM vs. Control 
>0.99 GDM-EVOO vs. GDM 
0.12 GDM-EVOO vs. Control 
Blood triglycerides 
at term (mg/dL) 
238±6 292±21 231±14 
0.04 GDM vs. Control 
0.02 GDM-EVOO vs. GDM 










0.14 GDM-EVOO vs. GDM 
Table 1. Pregnancy and metabolic control data. Data are presented as mean ± SEM. Statistica l 
analysis: One-way ANOVA in conjunction with Bonferroní s test or Student´s t test on continuous 
variables and chi-square test for categorical variables.  
  























age at delivery 
(weeks) 38.1±0.3 37.6±0.3 37.8±0.3 
0.73 GDM vs. Control 
>0.99 GDM-EVOO vs. GDM 
>0.99 GDM-EVOO vs. Control 
Cesarean 
delivery 40% (6/15) 47% (7/15) 40% (6/15) 0.91 
Maternal 

















3312±168 3205±113 3332±135 
>0.99 GDM vs. Control 
>0.99 GDM-EVOO vs. GDM 
>0.99 GDM-EVOO vs. Control 
Placental 
weight (g) 
599±27 613±40 672±32 
>0.99 GDM vs. Control 
>0.66 GDM-EVOO vs. GDM 
>0.39 GDM-EVOO vs. Control 
Table 2. Pregnancy outcomes. Data are presented as mean ± SEM. Statistical analysis: One-way ANOVA in conjunction 
with Bonferroní s test on continuous variables and chi-square test for categorical variables. Maternal complications 
considered: pyelonephritis, cholestasis, preeclampsia, pregnancy-induced hypertension and threatened preterm labor. 
Neonatal complications considered: shoulder dystocia, brachial plexus injury, clavicle fracture, respiratory distress 
syndrome, intrauterine growth restriction, hypoglycemia, hyperbilirubinemia, birth defects and perinatal mortality.  
 
 




FIGURE 1. Protein expression of PPARγ and PPARα and expression of microRNAs that target these PPAR 
isotypes in term placentas of GDM patients that received or not a maternal diet enriched in three 
tablespoons of EVOO per day from weeks 24-28 of pregnancy until term and in controls. a. PPARγ. b. 
PPARα. c. miR-130a (targeting PPARγ). d. miR-518d (targeting PPARα). Values represent mean ± SEM. 
Statistical analysis: one-way ANOVA in conjunction with Bonferroni´s test.  ‡P<0.05 and ‡‡P <0.01 vs. 
Control, §P<0.05, §§P<0.01 vs. GDM. 













FIGURE 2. Evaluation of proinflammatory and prooxidant markers in term placentas of GDM patients that 
received or not a maternal diet enriched in three tablespoons of EVOO per day from weeks 24-28 of 
pregnancy until term and in controls. a. TNF-α. Representative images and densitometric analysis. b. IL-1β. 
Representative images and densitometric analysis. c. Nitric oxide production (evaluated through the 
determination of its stable metabolites nitrates/nitrites). d. Gene expression of Cu-Zn SOD. Values represent 
mean ± SEM. Statistical analysis: one-way ANOVA in conjunction with Bonferroni´s test. ‡P<0.05 and 
‡‡P<0.01, ‡‡‡P<0.001 vs. Control. §P<0.05 and §§P<0.01, §§§P<0.001 vs. GDM. 













FIGURE 3. Gelatinase activity of MMP-2 and MMP-9 in term placentas and umbilical cord blood in GDM 
patients that received or not a maternal diet enriched in three tablespoons of EVOO per day from weeks 24-
28 of pregnancy until term and in controls. a. MMP-2 in term placentas. b. MMP-9 in term placentas. c. MMP-
2 in umbilical cord blood. d. MMP-9 in umbilical cord blood. Values represent mean ± SEM. Statistical 
analysis: one-way ANOVA in conjunction with Bonferroni´s test. ‡P<0.05 and ‡‡P<0.01 vs. Control. 
§P<0.05 and §§P<0.01 vs. GDM. 
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